Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 ...

Now, working with lung cancer patients, she can tell them she went through something similar and offer words of encouragement about the doctors who not only work with her but also treated her.

plus Nivolumab and CAPOX as the first-line treatment for the patients with advanced G/GEJ cancer (TranStar102). The updated data continues to show encouraging efficacy from previously disclosed data ...

"These findings are encouraging and demonstrate that Commission on Cancer accreditation increases compliance with guideline-based care and improves outcomes for cancer patients. This work shows ...